$3.17
-0.13[-3.94%]
At close: May 20
$3.17
0[0.00%]
After Hours: 4:38PM EDT
Cellectar Biosciences
(NASDAQ:CLRB)Latest News for Cellectar Biosciences Stock (NASDAQ:CLRB)
Cellectar Biosciences Stock (NASDAQ: CLRB)
Categories: All
Tuesday, May 14, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
- Cellectar Biosciences Says Cash and Cash Equivalents Of $9.6M And Funds Generated By Warrants Exercised In 2023 Of $22.9M Is Expected To Provide Cash Runway Into Q4 2024Benzinga Newsdesk - Mar 27, 2024, 6:52AM
- Cellectar Biosciences Q4 EPS $(0.40) Beats $(0.59) EstimateBenzinga Newsdesk - Mar 27, 2024, 6:51AM
- Earnings Scheduled For March 27, 2024Benzinga Insights - Mar 27, 2024, 5:02AM
Tuesday, March 26, 2024
Monday, March 04, 2024
- Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's WhyVandana Singh - Mar 4, 2024, 1:48PM
- Roth MKM Reiterates Buy on Cellectar Biosciences, Maintains $20 Price TargetBenzinga Newsdesk - Mar 4, 2024, 11:44AM
- Cellectar Biosciences Announced That Iopofosine I 131 In Combination With External Beam Radiation Therapy Was Safe And Tolerated In Phase 1 Trial In Recurrent Head And Neck CancerBenzinga Newsdesk - Mar 4, 2024, 6:42AM
Thursday, January 25, 2024
Monday, January 08, 2024
- Cellectar Biosciences shares are trading higher after the company announced the CLOVER WaM study met its primary endpoint.Benzinga Newsdesk - Jan 8, 2024, 2:03PM
- Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?Vandana Singh - Jan 8, 2024, 11:15AM
- Cellectar Biosciences Announces Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's MacroglobulinemiaBenzinga Newsdesk - Jan 8, 2024, 6:32AM
Tuesday, December 12, 2023
Thursday, November 02, 2023
- Cellectar Biosciences Sees Preliminary Q3 2023 Cash And Cash Equivalents $19M Down From $19.9M YoY; R&D Exepsne $7.3M Up From $5.4M YoY; G&A Expense $2.1M Down From $2.4M YoYBenzinga Newsdesk - Nov 2, 2023, 8:14AM
- Cellectar To Release Top-Line Data From WM Pivotal Trial During The JP Morgan Healthcare ConferenceBenzinga Newsdesk - Nov 2, 2023, 8:11AM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Tuesday, October 17, 2023
Thursday, October 05, 2023
Friday, September 22, 2023
Monday, September 18, 2023
Wednesday, September 06, 2023
Tuesday, September 05, 2023
- Crude Oil Rises 1%; Verb Technology Shares Spike HigherLisa Levin - Sep 5, 2023, 2:30PM
- Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Sep 5, 2023, 1:34PM
- Cellectar Biosciences shares are trading higher after the company announced up to $103 million in private placement financing.Benzinga Newsdesk - Sep 5, 2023, 1:21PM
- Nasdaq Turns Higher; US Factory Orders Fall 2.1% In JulyLisa Levin - Sep 5, 2023, 12:16PM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Sep 5, 2023, 9:06AM
- Cellectar Biosciences Announces Up To ~$103M Private Placement Financing With Certain Institutional InvestorsHappy Mohamed - Sep 5, 2023, 8:22AM
Monday, August 14, 2023
Thursday, June 29, 2023
- Cellectar Biosciences Director Awarded $47K Worth of Stock OptionsBenzinga Insights - Jun 29, 2023, 11:03AM
- Director at Cellectar Biosciences Acquires Company Stock Options Worth 25,000 SharesBenzinga Insights - Jun 29, 2023, 11:03AM
- Board Member at Cellectar Biosciences Acquires Company Stock Options Worth 37,500 SharesBenzinga Insights - Jun 29, 2023, 11:03AM
- Board Member at Cellectar Biosciences Acquires Company Stock Options Worth 25,000 SharesBenzinga Insights - Jun 29, 2023, 11:03AM